Within 10 minutes of the first count the subjects sat in front of a large field of view gamma camera (Ohio-Nuclear 110) linked to a computer (Nodecrest V77-600) and the initial topographical distribution of the radioaerosol within the lungs was expressed quantitatively as a penetration index.'7 This is defined as the ratio of radioactivity in the outer region of the lungs to that in the inner region divided by the ratio of radioactive krypton-81m (half life 13 seconds) in the two regions.
Fifteen minutes before inhaling the radioaerosol subjects were asked to swallow 5 ml of an elixir (glycerol based) containing 10 MMF2,7,-maximum mid expiratory flow. (3) 52 ( indices were no different after temazepam and after placebo (table 1). The mean (SE) radioaerosol inspiratory flow rate, alveolar deposition, and penetration index for the study group for the placebo and temazepam study days are shown in table 2. The radioaerosol was inspired at a significantly higher flow rate on the placebo day than on the temazepam day (p < 0-01). There were no significant differences between the two study days for alveolar deposition or penetration index. Three subjects recorded dry, unproductive coughs or throat clearing, or both, during the six hour observation periods on both the placebo and the temazepam days. The frequency of coughing was similar within subjects on the two study days.
Tracheobronchial clearance was significantly slower over the first three hours after treatment with temazepam than with placebo (mean (SE) AUCO3 132% (1I1%)/h for placebo and 161% (10%)/h for temazepam; p < 0 05). Although the AUCO-6 for the six hour observation period (figure) was greater (that is, clearance was slower) after temazepam (200% (16%)/h) than after placebo (166% (15%)/h) the difference was not significant ( Discussion Tracheobronchial clearance of deposited radioaerosol depends on the initial distribution of the radioaerosol within the lung. This distribution is a function ofthe physical properties of the aerosol, the mode of inhalation, and the patency of the airways."' The radioaerosol was inspired at a higher flow rate with placebo than with temazepam, but the difference was small and alveolar depositions and penetration indices during the two study days were similar (table 2) . Thus the proportions of radioaerosol available for clearance by mucus transport after placebo and temazepam administration were similar.
The AUC was used as an index of tracheobronchial clearance as it reflects clearance over an observation period and avoids multiple statistical testing at numerous time points.
Lung mucociliary clearance was less (mean percentage increase in AUC 25%) during the first three hours after temazepam administration than after placebo. Although a similar reduction in the area under the curve was seen over the six hours of observation it failed to attain statistical significance.
A study on the pharmacokinetics of temazepam elixir in healthy male volunteers showed a mean time to peak plasma concentration of 1 6 hours.20 The mean drug distribution and terminal phase half lives were about 1-3 and 9 hours respectively.
The tracheobronchial retention curves diverged over the first two hours after radioaerosol administration, with convergence of the curves thereafter. The maximum separation between the tracheobronchial retention curves occurred at about 1-5 hours, and this coincides with the peak plasma concentrations. mucus clearance. 
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